NCT07467772 2026-04-21Ph 2 Elacestrant in ER Positive Uterine SarcomasDana-Farber Cancer InstitutePhase 2 Recruiting30 enrolled
NCT02834013 2026-04-13Nivolumab and Ipilimumab in Treating Patients With Rare TumorsNational Cancer Institute (NCI)Phase 2 Active not recruiting818 enrolled
NCT07089992 2025-12-16A Study of Pembrolizumab in People With Ultra-Rare SarcomasMemorial Sloan Kettering Cancer CenterPhase 2 Recruiting32 enrolled
NCT06683846 2025-08-24Ivonescimab in the Treatment of Multiple Advanced TumorsFudan UniversityPhase 2 Recruiting400 enrolled
NCT01690871 2013-08-02A Phase II Study of Orally Administered BEZ235 Monotherapy in Patients With Metastatic or Unresectable Malignant PEComaNovartisPhase 2 Withdrawn